2026-01-18, Sun.

Top Stories       Business       Culture & Life       Science & Technology       World

Lecture

Notification

 

NEWS > Science & Technology


Sinovac: Antigua Court Grants Board Control Pending Trial Over Disputed 2025 Shareholder Meeting

Date: 2026-01-17

BEIJING -- Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, announced that the Antigua High Court has ordered that the directors Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Mr. Andrew Y. Yan and Mr. Yin Weidong (collectively, the Board), will comprise the Board of the Company until the trial listed in late April/early May 2026.

The Antigua High Court decision arises from a hearing that took place on 27 October 2025, at which applicants SAIF Partners IV L.P., OrbiMed Partners Master Fund Limited and 1Globe Capital LLC each sought injunctions to confirm the composition of their respective favoured Boards, pending determination of a dispute over the outcome of the Company’s Special Shareholders Meeting on 8 July 2025 (the SSM Dispute).

The hearing of the SSM Dispute has been scheduled to take place in the Antigua High Court in late April/early May 2026, with judgment to be delivered by the Court thereafter.

A Board meeting was held on 17 December 2025 to reiterate its unwavering commitment to shareholder value creation, to work diligently with the management and the advisors of the Company, to make efforts to restore trading of the Company‘s shares on NASDAQ, to explore opportunities to properly and legally resolve the Company’s ongoing disputes, and to take all necessary steps, including to facilitate to reach agreements among all parties, to ensure the stable operations of the Company and to create greater value for shareholders through cooperation.

Mr. Andrew Y. Yan, Chairman of the Board of SINOVAC, stated, “The current Board is committed to the long-term and sustainable development of the Company. The Board and its Audit Committee will collaborate closely with the auditors to complete audit. The Board trusts and supports the CEO and management team in continuing to implement the Company’s current development strategy, maintaining operational stability, continuously enhancing shareholder value through sustained business growth, and collaboratively promoting the comprehensive development of the Company.”



 to the Top List of News

Barilla Opens Its New Innovation Center to Drive Food Innovation Worldwide
GE HealthCare, Indonesia Partner to Expand Care with 300+ Advanced CT Scanners
Esco Aster, Shine-On Biomedical Ink cGMP Deal for First-in-Class HLA-G Exosome Drug Platform
1GLOBAL Empowers Revolut to Offer Mobile Plans in Poland
Sinovac: Antigua Court Grants Board Control Pending Trial Over Disputed 2025 Shareholder Meeting
SLB Enters Collaboration Agreement to Accelerate New Digital Solutions
Guinea Emerges as West Africa's New Digital Transformation Powerhouse

 

Novotech Issues White Paper to Help Sponsors Strengthen Early-Phase On...
Smarter Cars, Better Journeys: LG and aiMotive Reveal the Next-Gen HPC...
Parse Biosciences, Codebreaker Labs Partner on Scaled Single Cell Tran...
Tecnotree Emerges as CX Catalyst Winner for Impact at The Fast Mode Aw...
Biocytogen Completes STAR Market IPO, Becoming the First ¡°H+A¡± Globa...
Tahoe Therapeutics Picks Parse Biosciences¡¯ GigaLab, Targets 300M Sin...
DNP Achieves 10nm Line Pattern Resolution on Nanoimprint Template for ...

 

 

60, Gamasanro 27gil, Guro-gu, Seoul, Korea, e-mail: news@newsji.com

Copyright, NEWSJI NETWORK.

.